tradingkey.logo
tradingkey.logo
Search

Compass Pathways PLC

CMPS
Add to Watchlist
11.000USD
+0.150+1.38%
Market hours ETQuotes delayed by 15 min
680.73MMarket Cap
LossP/E TTM

Compass Pathways PLC

11.000
+0.150+1.38%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.36%

5 Days

-9.70%

1 Month

-25.79%

6 Months

+63.90%

Year to Date

+59.39%

1 Year

+153.41%

Key Figures
10.800Open
11.130High
1.77MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.86%Turnover Ratio
10.850Prev. Close
10.650Low
12.34MTurnover
LossP/E Static
2.08P/B
0.00%Div Yield TTM
-42.03%ROA
12.48052wk High
0.84Volume Ratio
-155.12MNet Profit
61.88MShares
-2.0497EPS TTM
2.46Beta
-68.48%ROE
2.25052wk Low
4.42%Amplitude
--Gross Margin
680.73MMarket Cap
-6.26Reward/Risk
4.47%Risk Rate

Compass Pathways PLC News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 17 analysts
Buy
Current Rating
22.861
Target Price
+103.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Compass Pathways PLC
CMPS
17
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.601
Sell
RSI(14)
36.472
Neutral
STOCH(KDJ)(9,3,3)
7.476
Oversold
ATR(14)
0.817
High Vlolatility
CCI(14)
-125.084
Sell
Williams %R
93.516
Oversold
TRIX(12,20)
-0.361
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
11.404
Sell
MA10
11.896
Sell
MA20
12.681
Sell
MA50
12.398
Sell
MA100
9.836
Buy
MA200
8.160
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Compass Pathways PLC Info

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Ticker SymbolCMPS
CompanyCompass Pathways PLC
CEONath (Kabir)
Websitehttps://compasspathways.com/

Shareholders

Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.49%
Deep Track Capital LP
5.44%
Atai Life Sciences AG
3.53%
BIT Capital GmbH
2.59%
ARK Investment Management LLC
2.45%
Other
79.51%

FAQs

What is the current price of Compass Pathways PLC (CMPS)?

The current price of Compass Pathways PLC (CMPS) is 10.85.

What is the symbol of Compass Pathways PLC?

The ticker symbol of Compass Pathways PLC is CMPS.

What is the 52-week high of Compass Pathways PLC?

The 52-week high of Compass Pathways PLC is 12.48.

What is the 52-week low of Compass Pathways PLC?

The 52-week low of Compass Pathways PLC is 2.25.

What is the market capitalization of Compass Pathways PLC?

The market capitalization of Compass Pathways PLC is 1.46B.

Is Compass Pathways PLC (CMPS) currently rated as Buy, Hold, or Sell?

According to analysts, Compass Pathways PLC (CMPS) has an overall rating of Buy, with a price target of 22.86.

What is the Earnings Per Share (EPS TTM) of Compass Pathways PLC (CMPS)?

The Earnings Per Share (EPS TTM) of Compass Pathways PLC (CMPS) is -3.08.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.